JBIO — Jade Biosciences, Inc.
$16.14
+$0.27 (+1.70%)
Jade Biosciences, Inc. operates as a biotechnology company that develops therapies for inflammation and immunology indications in patients living with autoimmune diseases. It develops JADE101, a monoclonal antibody to block the A PRoliferation Inducing Ligand protein, which is in phase 1 clinical trial.
Market Cap
$1.03B
Forward P/E
-6.1x
52-Week Range
N/A
JBIO Price History
Revenue vs. Net Income
$0
Revenue · FY2025
Annual. Net margin is shown under each year.
Free Cash Flow
-$94.9M
FCF · FY2025
Annual. FCF margin is shown under each year.
Return on Capital Employed (ROCE)
-34.1%
ROCE · FY2025
Annual. Green above 0%, red below. Dashed line marks the 15% compounder threshold.
Total Assets vs. Total Liabilities
20.3x
Assets ÷ liabilities · FY2025
Annual. What the company owns against what it owes. Assets ÷ liabilities is shown under each year.
CapEx as % of Revenue
Annual. Green at or under the 5% maximum target, red above it.
Shares Outstanding
31.4M
Diluted shares · FY2025
Only one year of share data is available, so no change can be shown yet.
